Stocktoria
CORCEPT THERAPEUTICS INC CORT
CORCEPT THERAPEUTICS INC (CORT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $761.4M at a 13.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.81 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-30 | Piper Sandler | Overweight (reit) |
| 2026-07-30 | Canaccord Genuity | Buy (main) |
| 2026-07-30 | HC Wainwright & Co. | Buy (main) |
| 2026-07-29 | Canaccord Genuity | Buy (main) |
| 2026-07-27 | Wolfe Research | Underperform (down) |
| 2026-05-28 | Canaccord Genuity | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.382 |
| Retained earnings / assets | 0.769 |
| EBIT / assets | 0.054 |
| Equity / liabilities | 3.43 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
About CORCEPT THERAPEUTICS INC
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
FAQ
Is CORT financially healthy?
CORCEPT THERAPEUTICS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CORT pay a dividend?
No, CORCEPT THERAPEUTICS INC does not currently pay a dividend.
How profitable is CORT?
In FY2025, CORCEPT THERAPEUTICS INC had a net margin of 13.1% and a return on equity of 15.4%.
Is CORT overvalued or undervalued?
CORCEPT THERAPEUTICS INC trades at about 136.8× trailing earnings — above its 10-year norm (10-year range 16.5×–101.6×, median 26.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CORT?
The average Wall-Street price target for CORCEPT THERAPEUTICS INC is $135.25, about 20.6% above the recent price, from 4 analysts (consensus: buy).
Is CORT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CORCEPT THERAPEUTICS INC: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 94.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.